-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis projects 5% cc net sales CAGR for 2026-2031

PUBT·11/19/2026 06:02:24
Listen to the news
Novartis projects 5% cc net sales CAGR for 2026-2031
  • Novartis forecasts 5% compound annual sales growth at constant currencies for 2026-2031, with core operating income margin returning to 40%+ by 2029.
  • Kesimpta peak sales guidance increased to USD 8 billion from USD 6 billion.
  • Scemblix and Leqvio peak sales forecasts each rose to USD 5 billion from USD 4 billion.
  • Nine marketed assets now have peak sales potential of USD 3-10 billion, following Rhapsido/remibrutinib's recent upgrade to USD 8 billion.
  • More than 35 potentially submission-enabling readouts through 2031 are expected to support sustained mid-single-digit sales growth over the long term.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190100OMX_____CNEWS_EN_GNW1001304397_en) on November 19, 2026, and is solely responsible for the information contained therein.